Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis.

IF 1.4 4区 医学 Q4 IMMUNOLOGY
International Journal of STD & AIDS Pub Date : 2025-04-01 Epub Date: 2025-02-03 DOI:10.1177/09564624251315781
Tanvi Vaidya, Monisha Madhumita
{"title":"Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis.","authors":"Tanvi Vaidya, Monisha Madhumita","doi":"10.1177/09564624251315781","DOIUrl":null,"url":null,"abstract":"<p><p>Tofacitinib is a Janus kinase 3 (JAK3) inhibitor effective in treating alopecia areata (AA) by promoting hair regrowth. Its mechanism may involve upregulation of vascular endothelial growth factor (VEGF) and reduction of inflammation. However, the range of effects, particularly on hair growth in specific populations, remains under-investigated. We describe a patient with HIV, well-controlled on antiretroviral therapy, who developed hirsutism after starting tofacitinib for AA. This unexpected side effect of hypertrichosis was completely resolved after discontinuing the medication and undergoing a single session of laser hair removal (LHR). This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. The case emphasizes the need for careful monitoring of hair growth and other potential side effects in patients on tofacitinib, especially those with underlying immune-modulating conditions. It also suggests that LHR can be an effective treatment for medication-induced hirsutism.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"423-426"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of STD & AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09564624251315781","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tofacitinib is a Janus kinase 3 (JAK3) inhibitor effective in treating alopecia areata (AA) by promoting hair regrowth. Its mechanism may involve upregulation of vascular endothelial growth factor (VEGF) and reduction of inflammation. However, the range of effects, particularly on hair growth in specific populations, remains under-investigated. We describe a patient with HIV, well-controlled on antiretroviral therapy, who developed hirsutism after starting tofacitinib for AA. This unexpected side effect of hypertrichosis was completely resolved after discontinuing the medication and undergoing a single session of laser hair removal (LHR). This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. The case emphasizes the need for careful monitoring of hair growth and other potential side effects in patients on tofacitinib, especially those with underlying immune-modulating conditions. It also suggests that LHR can be an effective treatment for medication-induced hirsutism.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
144
审稿时长
3-6 weeks
期刊介绍: The International Journal of STD & AIDS provides a clinically oriented forum for investigating and treating sexually transmissible infections, HIV and AIDS. Publishing original research and practical papers, the journal contains in-depth review articles, short papers, case reports, audit reports, CPD papers and a lively correspondence column. This journal is a member of the Committee on Publication Ethics (COPE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信